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OBJECTIVE— To summarize the efficacy of metformin in reducing BMI and cardiometa-
bolic risk in obese children and adolescents without diabetes.
RESEARCH DESIGN AND METHODS— We performed a systematic review and
meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of 6 months dura-
tion in obese subjects age19 years without diabetes were included. Our primary outcomes of
interest include changes in BMI and measures of insulin sensitivity.
RESULTS— Five trials met inclusion criteria (n 320 individuals). Compared with placebo,
metformin reduced BMI by 1.42 kg/m2 (95% CI 0.83–2.02) and homeostasis model assessment
insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75–3.26).
CONCLUSIONS— Metformin appears to be moderately efficacious in reducing BMI and insu-
lin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-
term studies in different populations are needed to establish its role in the treatment of overweight
children.
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M etformin has been shown to reduceweight gain, hyperinsulinemia, andhyperglycemia in adults with type 2
diabetes (1,2) and to reduce progression
from impaired glucose tolerance to diabetes
in those without diabetes (3). These benefits
have led to an increase in the use of met-
formin in obese children with hyperinsulin-
emia. However, obesity is not a licensed
indication for metformin in the U.K. or the
U.S., and its use has proceeded faster than
the evidence of its benefits. We undertook a
systematic review of randomized controlled
trials (RCTs) investigating the efficacy of
metformin for reducing BMI and cardiom-
etabolic risk in obese children without
diabetes.
RESEARCH DESIGN AND
METHODS— We searched Ovid
MEDLINE, EMBASE, the Cochrane Regis-
ter of Controlled Trials, the metaRegister of
Controlled Trials, and key journals pub-
lished before December 2008 (online ap-
pendix Tables 1 and 2 available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-0258/DC1). We included double-
blind RCTs of 6 months duration with
obese subjects age 19 years without dia-
betes and without secondary or syndromic
causes of obesity. Primary outcomes of in-
terest were BMI (weight in kilograms di-
vided by the square of height in meters) and
measures of insulin sensitivity. Secondary
outcomes included fat mass, blood pres-
sure, fasting lipids, and adverse effects.
Where three or more studies reported
a common outcome, treatment effect was
explored in a meta-analysis (Stata Statis-
tical Software 10.1; StataCorp, College
Station, TX), pooling data from the end of
the follow-up period for trial completers.
A random-effects model was selected.
Sensitivity analyses were performed using
fixed-effects models and by dose of met-
formin (1,000 vs. 2,000 mg), age of par-
ticipants (12–19 vs. 12 years), co-
intervention (metformin vs. metformin
co-intervention), baseline BMI (mean
35 vs. 35 kg/m2), and by excluding
one study reporting greater treatment ef-
fects than the other studies (4).
RESULTS— Five studies published
between 2001 and 2008 met the inclu-
sion criteria (4 – 8). This included one
crossover trial (5).
Three studies took place in the U.S.
(6–8), and one each in Australia (5) and
Turkey (4). All trials lasted 6 months with
metformin doses from 1,000–2,000 mg/
day. Three studies used lifestyle co-
interventions in either trial arms (4,7,8).
Two studies included adolescents (ages
12–19 years) (6,7), one looked at younger
children (ages 6–12 years) (6), and the
others spanned ages 9–18 years. In the
U.S. and Australian studies, a large pro-
portion of participants (45–90%) were
from ethnic backgrounds with high prev-
alence of metabolic syndrome (African
American, Hispanic, or Asian). All partic-
ipants were hyperinsulinemic or insulin
resistant. Sample size ranged from 28–
120 participants at randomization; in to-
tal there were 365 participants and 320
trial completers. Mean attrition rates were
11% in metformin groups and 16% in
placebo groups.
In the pooled analysis, metformin re-
duced BMI by a mean of 1.42 kg/m2 (95%
CI 0.83–2.02) compared with placebo
(I2 56.2%; n 342) (Fig. 1). Sensitivity
analyses did not reveal notable differences
by age, dose, or baseline BMI. When the
outlier result was excluded, metformin
reduced BMI by 1.15 kg/m2 (0.73–1.57,
I2 0%). Reduction in fasting insulin was
greater in metformin than placebo groups
in three studies, but evidence for a treat-
ment effect was weak (5.30 U/ml
[95% CI 11.96 to 1.36], I2  78.7%;
n  257) (4–7). Pooled metformin effect
on the homeostasis model assessment of
insulin resistance (HOMA-IR) score was
2.01 (95% CI 3.26 to 0.75, I2 
49.5%; n  234) (4,6,8) and 1.28
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(2.55 to0.21, I2 0%) if the Turkish
study was excluded.
Pooled mean metformin effect on to-
tal cholesterol was 0.19 mmol/l (95%
CI 0.38 to 0.01, I2  0%; n  234)
(4,6,7). Analyses did not provide strong
evidence for a treatment effect on fasting
glucose, HDL cholesterol, triglyceride
levels, or blood pressure. There was insuf-
ficient data to comment on body fat out-
comes. Gastrointestinal problems were
the most common reported side effect (in
20–30%) and were more frequently re-
ported in metformin than in placebo
groups (risk difference 10–14%) (6,7).
Only one participant reported gastroin-
testinal problems as the reason for leaving
a study (7).
CONCLUSIONS— Our meta-analy-
sis provides some support for a beneficial
metformin effect on obesity outcomes
among hyperinsulinemic children and
adolescents. Treatment over 6 months
may be efficacious in reducing BMI by
1.42 kg/m2 (equivalent to 0.4 SD, based
on SD for BMI in U.K. and U.S. adoles-
cents) and HOMA-IR score by 2.01 (0.6
SD) (9). Metformin use was also associ-
ated with a small reduction in total cho-
lesterol level (0.26 SD) (10), but these
are unadjusted measures, and it is not
possible to determine whether the effects
are secondary to reductions in BMI and
HOMA-IR or attributable to other factors.
To our knowledge, the effects of met-
formin on BMI in obese children without
diabetes have been synthesized in only
one published review based on three
studies (11), which identified no treat-
ment effect at 6 months (0.17 kg/m2
[95% CI 0.62 to 0.28]).
Metformin may not be as effective as
behavioral interventions in reducing BMI: a
meta-analysis of behavioral interventions in
obese adolescents reported an effect of
3.04 kg/m2 (95% CI3.14 to2.94) at
6 months, which was maintained at 12
months follow-up (12). When compared
with drugs that are licensed for obesity,
metformin has moderate effect: meta-
analyses of RCTs reported an orlistat effect
of 0.76 kg/m2 (1.07 to 0.44) and a
sibutramine effect of1.66 kg/m2 (1.89
to1.43) at 6 months (12).
The results of this review must be in-
terpreted with caution: the studies were
short-term and based on small samples;
participants were mainly from the U.S.,
and large portions were from ethnic back-
grounds known to be at increased risk of
metabolic disorders, limiting the general-
izability of findings; and the studies pre-
sented unadjusted measures without
intention-to-treat analyses, which may
have overestimated treatment effects.
Metformin may be efficacious in re-
ducing BMI and insulin resistance among
obese hyperinsulinemic children and ad-
olescents in the short term. Larger, long-
term studies across different populations
are needed to establish the role of met-
formin as therapy for obesity and cardio-
metabolic risk in young people.
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